Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

A promising path to fighting COVID and other coronaviruses may have been based on a serious mistake. Scientists had zeroed in on a part of the virus called the NiRAN domain, believed to be a ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

WASHINGTON — Law enforcement agencies and associations are pushing for Congress to reject a Trump administration proposal to cut funding for a program aimed at reducing drug trafficking and illicit ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. “The medications should be available, the question is at what price ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.